We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

BioXcel Therapeutics Inc (BTAI) USD0.001

Sell:$3.15 Buy:$3.26 Change: $0.03 (0.94%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $0.03 (0.94%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $0.03 (0.94%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. BXCL501 is also being developed for the acute treatment of agitation associated with Alzheimer’s disease, and as an adjunctive treatment for major depressive disorder. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia. Under its subsidiary, OnkosXcel Therapeutics, LLC, the Company is developing BXCL701, an investigational, oral innate immune activator that is being developed as a potential therapy for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Contact details

555 Long Wharf Dr
United States
+1 (203) 6438060

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$99.35 million
Shares in issue:
30.38 million
United States
US dollar

Key personnel

  • Vimal Mehta
    President, Chief Executive Officer, Director
  • Richard Steinhart
    Chief Financial Officer, Senior Vice President
  • Vincent O'Neill
    Executive Vice President, Chief of Product Development and Medical Officer
  • Frank Yocca
    Senior Vice President, Chief Scientific Officer
  • Javier Rodriguez
    Senior Vice President, Chief Legal Officer, Corporate Secretary
  • Matthew Wiley
    Senior Vice President, Chief Commercial Officer
  • Robert Risinger
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.